Streetbeat News

Analyst Ratings

MLTX

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on MoonLake (NASDAQ:MLTX) and maintained a price target of $86.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 12:17 pm

LGF

Goldman Sachs analyst Brett Feldman maintains a Neutral rating on Lions Gate Entertainment Corporation Class A Voting Shares (NYSE:LGF) and raises the price target from $10 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 12:16 pm

LQDA

Wedbush analyst Andreas Argyrides has reiterated an 'Underperform' rating on Liquidia (NASDAQ:LQDA) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 12:16 pm

PSX

Argus Research analyst Bill Selesky maintains a 'Buy' rating on Phillips 66 (NYSE:PSX) and raises the price target from $125 to $134.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 14, 2023 | 12:15 pm

IONQ

Goldman Sachs analyst Toshiya Hari maintains a Neutral rating on IonQ (NYSE:IONQ) and raises the price target from $9 to $14.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 12:15 pm

HYLN

Goldman Sachs analyst Mark Delaney has maintained a 'Sell' rating on Hyliion Holdings (NYSE:HYLN) and lowered the price target from $1.75 to $1.25.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 12:13 pm

ACCD

Stephens & Co. analyst Jeff Garro has reiterated an Overweight rating on Accolade (NASDAQ:ACCD) and maintained a price target of $18.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 12:12 pm

STAA

Stephens & Co. analyst George Sellers has reiterated an Overweight rating on Staar Surgical (NASDAQ:STAA) and maintained a $57 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 12:11 pm

JSPR

Credit Suisse analyst Judah Frommer has reiterated an 'Outperform' rating on Jasper Therapeutics (NASDAQ:JSPR) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 12:08 pm

CDXS

Stifel analyst Daniel Arias maintains a 'Buy' rating on Codexis (NASDAQ:CDXS) but has lowered the price target from $9 to $5.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 12:08 pm